Avutometinib potassium
Based on 6 publication(s) in Google Scholar
Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC).
For research use only. We do not sell to patients.
- CAS No.: 946128-90-1
- Formula: C21H18FKN5O5S
- Molecular Weight:510.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Avutometinib potassium
More-
WB
-
Bio/Physico-chemical Assay
-
WB
-
Cell Proliferation/Viability Assay
All MEK Isoforms
More
Biological Activity
Chemical Information
-
CAS No. 946128-90-1
-
Molecular Weight 510.56
-
Formula C21H18FKN5O5S
-
SMILES
O=S(NC)(NC1=NC=CC(CC2=C(C)C3=CC=C(OC4=NC=CC=N4)C=C3OC2=O)=C1F)=O.[K]
-
Synonyms
Ro 5126766 potassium; CH5126766 potassium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Nat Cancer
The MEK-RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers. [Abstract]2026 Jan;7(1):116-130. PMID: 41482524
Avutometinib potassium purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2026 Jan;7(1):116-130. [Abstract]
Western blot analysis of MEK immunoprecipitants depicting the modulation of MEK–BRAF and MEK–CRAF interactions in HCT-116 cells treated with DMSO, trametinib (10 nM), Avutometinib (30 nM), trametiglue (3 nM) or IK-595 (3 nM) for 4 h. A representative image of three independent experiments is shown.
Avutometinib potassium purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2026 Jan;7(1):116-130. [Abstract]
DMSO–inhibitor KD ratios obtained from an AlphaLISA biochemical assay measuring the interaction between MEK1 and BRAF (top) or CRAF (bottom) proteins following treatment with IK-595 (n = 1 sample per condition with nine biological replicates), trametinib (n = 1 sample per condition with five biological replicates) or Avutometinib (0.01-1 μM; 30 min) (n = 1 sample oer condition with four biological replicates). The results demonstrated that IK-595 and Avutometinib stabilized MEK1 with both BRAF and CRAF, whereas trametinib disrupted these interactions.
Avutometinib potassium purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2026 Jan;7(1):116-130. [Abstract]
Western blot quantification of MEK phosphorylation normalized to total MEK protein levels in HCT-116 cells treated with DMSO, Avutometinib (30 nM), trametinib (10 nM), trametiglue (3 nM), mirdametinib (25 nM), binimetinib (50 nM), selumetinib (550 nM), cobimetinib (320 nM) or IK-595 (3 nM) for 4 or 48 h (n = 1 sample per condition in two biological replicates).
-
Nat Chem Biol
2026 May 12:10.1038/s41589-026-02212-2. PMID: 42120500 -
Clin Sci (Lond)
A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIPK1 and alleviates dextran sulfate sodium-induced colitis. [Abstract]2019 Apr 16;133(8):919-932. PMID: 30944150 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112
Avutometinib potassium purchased from MedChemExpress. Usage Cited in: Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
CEP-32496, Avutometinib (Ro 5126766) (0.1-10 μM; 1 h) and PLX8394 didn’t inhibit necroptosis in L929 cells. L929 or HT-29 cells were pretreated with DMSO or Nec-1 or indicated inhibitors for 1h, then stimulated with T/Z for 3 hours or T/S/Z for 8 hours, respectively. Then cell viability was determined by CCK8 assay.
-
-
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)